Comparison of visual and automated assessment of HER2 status and their impact on outcome in primary operable invasive ductal breast cancer

Histopathology

Volumn 61, Issue 4, 2012, Pages 675-684

  Mohammed, Zahra M A ^a,b   Going, James J ^a   McMillan, Donald C ^a   Orange, Clare ^b   Mallon, Elizabeth ^b   Doughty Julie C , J C ^b   Edwards, Joanne ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b WESTERN INFIRMARY   (United Kingdom)

Author keywords

Automated IHC method; HER2 FISH test; Primary invasive breast cancer; Survival; Visual IHC method

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERBB2 PROTEIN, HUMAN;

ADULT; ARTICLE; CANCER SURVIVAL; COMPUTER ANALYSIS; CONTROLLED STUDY; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; HUMAN TISSUE; IMAGE ANALYSIS; IMMUNOHISTOCHEMISTRY; INTRADUCTAL CARCINOMA; MAJOR CLINICAL STUDY; MICROARRAY ANALYSIS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RECURRENCE FREE SURVIVAL; SCORING SYSTEM; TISSUE MICROARRAY; BREAST TUMOR; COMPARATIVE STUDY; DISEASE FREE SURVIVAL; FEMALE; IMAGE PROCESSING; METABOLISM; MIDDLE AGED; MORTALITY; PAGET NIPPLE DISEASE; PATHOLOGY; PROCEDURES;

BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; MIDDLE AGED; RECEPTOR, ERBB-2; TISSUE ARRAY ANALYSIS;

EID: 84871928270     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/j.1365-2559.2012.04280.x     Document Type: Article

References (30)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Estimating the world cancer burden: Globocan 2000. Int. J. Cancer 2001; 94; 153-156.
2. Cancerstats. http://info.cancerresearchuk.org/cancerstats/types/breast/incidence. Accessed 25 June 2008.
3. Lal P, Tan LK, Chen B. Correlation of HER-2 status with estrogen and progesterone receptors and histologic features in 3,655 invasive breast carcinomas. Am. J. Clin. Pathol. 2005; 123; 541-546.
4. Schnitt SJ. Traditional and newer pathologic factors. J. Natl Cancer Inst. Monogr. 2001; 30; 22-26.
5. Hammock L, Lewis M, Phillips C, Cohen C. Strong HER-2/neu protein overexpression by immunohistochemistry often does not predict oncogene amplification by fluorescence in situ hybridization. Hum. Pathol. 2003; 34; 1043-1047.
6. Laudadio J, Quigley DI, Tubbs R, Wolff DJ. HER2 testing: a review of detection methodologies and their clinical performance. Expert Rev. Mol. Diagn. 2007; 7; 53-64.
7. Francis G, Beadle G, Thomas S, Mengersen K, Stein S. Evaluation of oestrogen and progesterone receptor status in HER-2 positive breast carcinomas and correlation with outcome. Pathology 2006; 38; 391-398.
8. Santin AD, Bellone S, Roman JJ, McKenney JK, Pecorelli S. Trastuzumab treatment in patients with advanced or recurrent endometrial carcinoma overexpressing HER2/neu. Int. J. Gynaecol. Obstet. 2008; 102; 128-131.
9. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987; 235; 177-182.
10. Arpino G, Weiss H, Lee AV et al. Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance. J. Natl Cancer Inst. 2005; 97; 1254-1261.
11. Pritchard KI, Messersmith H, Elavathil L, Trudeau M, O'Malley F, Dhesy-Thind B. HER-2 and topoisomerase II as predictors of response to chemotherapy. J. Clin. Oncol. 2008; 26; 736-744.
12. Tovey SM, Witton CJ, Bartlett JMS, Stanton PD, Reeves JR, Cooke TG. Outcome and human epidermal growth factor receptor (HER) 1-4 status in invasive breast carcinomas with proliferation indices evaluated by bromodeoxyuridine labelling. Breast Cancer Res. 2004; 6; R246-R251.
13. Lacroix-Triki M, Mathoulin-Pelissier S, Ghnassia JP et al. High inter-observer agreement in immunohistochemical evaluation of HER-2/neu expression in breast cancer: a multicentre GEFPICS study. Eur. J. Cancer 2006; 42; 2946-2953.
14. Ellis MJ, Coop A, Singh B et al. Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial. J. Clin. Oncol. 2001; 19; 3808-3816.
15. Downs-Kelly E, Pettay J, Hicks D et al. Analytical validation and interobserver reproducibility of EnzMet GenePro: a secondgeneration bright-field metallography assay for concomitant detection of HER2 gene status and protein expression in invasive carcinoma of the breast. Am. J. Surg. Pathol. 2005; 29; 1505-1511.
16. Elkin EB, Weinstein MC, Winer EP, Kuntz KM, Schnitt SJ, Weeks JC. HER-2 testing and trastuzumab therapy for metastatic breast cancer: a cost-effectiveness analysis. J. Clin. Oncol. 2004; 22; 854-863.
17. Dobson L, Conway C, Hanley A et al. Image analysis as an adjunct to manual HER-2 immunohistochemical review: a diagnostic tool to standardize interpretation. Histopathology 2010; 57; 27-38.
18. Byrne A, Hilbert DR. Color realism and color science. Behav. Brain Sci. 2003; 26; 3-21.
19. Rinner O, Gegenfurtner KR. Time course of chromatic adaptation for color appearance and discrimination. Vision. Res. 2000; 40; 1813-1826.
20. Bolton KL, Garcia-Closas M, Pfeiffer RM et al. Assessment of automated image analysis of breast cancer tissue microarrays for epidemiologic studies. Cancer Epidemiol. Biomarkers Prev. 2010; 19; 992-999.
21. Camp RL, Dolled-Filhart M, King BL, Rimm DL. Quantitative analysis of breast cancer tissue microarrays shows that both high and normal levels of HER2 expression are associated with poor outcome. Cancer Res. 2003; 63; 1445-1448.
22. Joshi AS, Sharangpani GM, Porter K et al. Semi-automated imaging system to quantitate Her-2/neu membrane receptor immunoreactivity in human breast cancer. Cytometry A 2007; 71; 273-285.
23. Slodkowska J, Filas V, Buszkiewicz E et al. Study on breast carcinoma Her2/neu and hormonal receptor status assessed by automated image analysis systems: ACIS III (Dako) and ScanScope (Aperio). Folia Histochem. Cytobiol. 2010; 48; 19-25.
24. Turashvili G, Leung S, Turbin D et al. Inter-observer reproducibility of HER2 immunohistochemical assessment and concordance with fluorescent in situ hybridization (FISH): pathologist assessment compared to quantitative image analysis. BMC Cancer 2009; 9; 165.
25. Kononen J, Bubendorf L, Kallioniemi A et al. Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat. Med. 1998; 4; 844-847.
26. Kajo K, Zubor P, Barthova M, Plank L. Scoring index for prediction of HER-2 status in the invasive breast carcinoma. Exp. Oncol. 2007; 29; 281-286.
27. Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics 1977; 33; 159-174.
28. Faratian D, Kay C, Robson T et al. Automated image analysis for high-throughput quantitative detection of ER and PR expression levels in large-scale clinical studies: the TEAM Trial Experience. Histopathology 2009; 55; 587-593.
29. Konsti J, Lundin M, Joensuu H et al. Development and evaluation of a virtual microscopy application for automated assessment of Ki-67 expression in breast cancer. BMC Clin Pathol 2011; 11; 3.
30. Bishop JW, Marcelpoil R, Schmid J. Machine scoring of Her2/neu immunohistochemical stains. Anal. Quant. Cytol. Histol. 2002; 24; 257-262.